Directing delivery to selected cells
In vivo therapies deliver a therapeutic payload inside the body. INTACT® focuses on making delivery more selective so the payload can act where it is intended to.
Full platform nameIn vivo No off-target Therapy Achieving Cellular Targeting and delivery
Reaching the intended cells
INTACT® develops delivery systems that direct therapeutic payloads to selected cells while limiting unintended delivery elsewhere in the body.
Preserving therapeutic activity
The platform evaluates delivery quality by looking at activity in intended cells, uptake outside the target, and how clearly the delivery system can recognize the intended cells.
Developing investigational therapies
Qihan applies its delivery research to in vivo gene and cell therapy development. The pipeline tracks its in vivo CAR-T candidates by indication and stage.
Research & development
Early clinical evaluation
Qihan reports that INTACT® supports two investigational products in early clinical evaluation. The company has reported encouraging preliminary observations on activity and safety from these programs.
